Serviços Personalizados
Journal
Artigo
Indicadores
- Citado por SciELO
- Acessos
Links relacionados
- Similares em SciELO
Compartilhar
Medicina interna de México
versão impressa ISSN 0186-4866
Resumo
PEREZ-ZUNIGA, Juan Manuel et al. What results do patients who currently have chronic myeloid leukemia achieve?. Med. interna Méx. [online]. 2019, vol.35, n.5, pp.696-702. Epub 30-Abr-2021. ISSN 0186-4866. https://doi.org/10.24245/mim.v35i5.2610.
BACKGROUND:
Chronic myeloid leukemia is a myeloproliferative disease; the most effective drugs in the treatment of this disease are imatinib, nilotinib and dasatinib. Those drugs are available at the ISSSTE.
OBJECTIVES:
To know the number of chronic myeloid leukemia cases, to identify the clinical characteristics and to measure the degree of response to tyrosine kinase inhibitors and the survival.
MATERIAL AND METHOD:
A retrospective, cross-sectional, observational and explanatory study was done from 2005 to 2016, including patients over 18 years of age, with a diagnosis of chronic myeloid leukemia; with any of the three phases of the disease and treatment with any of the tyrosine kinase inhibitors.
RESULTS:
There were included 31 cases (55.2% women); the median age was 62 years; 72.4% were in chronic phase, 27.6% in accelerated phase and none in the blast phase. The haematological response was of 94.1%, 90% and 96%; the complete cytogenetic response at 12 months was of 69.2%, 60% and 57% and the mayor mo- lecular response was of 62.9%, 68.6%, 69.1% of the patients treated with imatinib, nilotinib or dasatinib, respectively. Disease-free survival at 5 years was of 83% and global survival at 5 years was of 94%.
CONCLUSION:
Independently of the inhibitor prescribed, the hematologic response is achieved in more than 90%, the complete cytogenetics around 60% at 12 months and major molecular almost 60% in a ISSSTE hospital.
Palavras-chave : Chronic myeloid leukemia; Imatinib; Nilotinib; Dasatinib.